Relationship betweeen the amount and location of macrophages and clinical outcome: subanalysis of the CLIMA-study.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 01 2022
Historique:
received: 02 06 2021
revised: 30 10 2021
accepted: 15 11 2021
pubmed: 20 11 2021
medline: 27 1 2022
entrez: 19 11 2021
Statut: ppublish

Résumé

The ability of optical coherence tomography (OCT) to recognize intraplaque macrophage infiltration is now well acknowledged. This post-hoc analysis of the CLIMA study aimed to address the clinical impact of the circumferential extension of OCT-defined macrophages and their location at one year follow-up. The multicentre CLIMA study enrolled 1003 patients undergoing OCT evaluation of the untreated proximal left anterior descending (LAD) coronary artery. Measurements of circumferential extension of macrophages and measurements of the distance from intima-lumen contour to macrophages string were performed at the plaque cross-section judged as containing the greatest amount of macrophages. The main study endpoint was a composite of cardiac death, myocardial infarction (MI) and/or target vessel revascularization (TVR). Patients with large macrophage arc (p = 0.001) and superficial macrophage arc (p < 0.001) showed a higher one-year incidence of the main one-year composite endpoint. Consistently hypertension (p = 0.018), family history of CAD (p = 0.046), diabetes mellitus (p = 0.036), lower ejection fraction (p = 0.009) and chronic kidney disease (p = 0.019) were more frequently found in patients experiencing the main composite endpoint. At multivariate Cox regression analysis, fibrous cap thickness < 75 μm (HR 2.51, 95% 1.46-4.32), presence of large (HR 1.97, 95%CI 1.16-3.35, p = 0.012) and superficial (HR 1.72, 95%CI 1.02-2.90; p = 0.040) macrophage arc remained independent predictors of the main composite endpoint. Large macrophage arc was associated with target LAD related MI. The present post-hoc analysis of the CLIMA showed that the circumferential extension of macrophages and their location are related to a composite endpoint of cardiac death, MI and/or TVR.

Sections du résumé

BACKGROUND
The ability of optical coherence tomography (OCT) to recognize intraplaque macrophage infiltration is now well acknowledged. This post-hoc analysis of the CLIMA study aimed to address the clinical impact of the circumferential extension of OCT-defined macrophages and their location at one year follow-up.
METHODS
The multicentre CLIMA study enrolled 1003 patients undergoing OCT evaluation of the untreated proximal left anterior descending (LAD) coronary artery. Measurements of circumferential extension of macrophages and measurements of the distance from intima-lumen contour to macrophages string were performed at the plaque cross-section judged as containing the greatest amount of macrophages. The main study endpoint was a composite of cardiac death, myocardial infarction (MI) and/or target vessel revascularization (TVR).
RESULTS
Patients with large macrophage arc (p = 0.001) and superficial macrophage arc (p < 0.001) showed a higher one-year incidence of the main one-year composite endpoint. Consistently hypertension (p = 0.018), family history of CAD (p = 0.046), diabetes mellitus (p = 0.036), lower ejection fraction (p = 0.009) and chronic kidney disease (p = 0.019) were more frequently found in patients experiencing the main composite endpoint. At multivariate Cox regression analysis, fibrous cap thickness < 75 μm (HR 2.51, 95% 1.46-4.32), presence of large (HR 1.97, 95%CI 1.16-3.35, p = 0.012) and superficial (HR 1.72, 95%CI 1.02-2.90; p = 0.040) macrophage arc remained independent predictors of the main composite endpoint. Large macrophage arc was associated with target LAD related MI.
CONCLUSION
The present post-hoc analysis of the CLIMA showed that the circumferential extension of macrophages and their location are related to a composite endpoint of cardiac death, MI and/or TVR.

Identifiants

pubmed: 34798205
pii: S0167-5273(21)01858-1
doi: 10.1016/j.ijcard.2021.11.042
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-12

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Laura Gatto (L)

Cardiovascular Sciences Department, San Giovanni Addolorata Hospital, Rome, Italy; Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Fernando Alfonso (F)

Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain.

Giulia Paoletti (G)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy; Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain; UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy.

Francesco Burzotta (F)

Department of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Alessio La Manna (A)

Cardio-Thoracic Vascular Department, Azienda ospedaliero-Universitaria "Policlinico Vittorio-Emanuele", University of Catania, Catania, Italy.

Simone Budassi (S)

Cardiovascular Sciences Department, San Giovanni Addolorata Hospital, Rome, Italy; Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Flavio Giuseppe Biccirè (FG)

Cardiovascular Sciences Department, San Giovanni Addolorata Hospital, Rome, Italy; Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy; Sapienza University of Rome, Rome, Italy.

Massimo Fineschi (M)

Department of Cardiovascular Diseases, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

Valeria Marco (V)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Franco Fabbiocchi (F)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Rocco Vergallo (R)

Department of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Alberto Boi (A)

Interventional Cardiology Unit, Ospedale Brotzu, Cagliari, Italy.

Giovanni Ruscica (G)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Francesco Versaci (F)

Cardiology Department, Santa Maria Goretti Hospital, Latina, Italy.

Nevio Taglieri (N)

Cardio-Thoracic Vascular Department, University Hospital of Bologna, Bologna, Italy.

Giuseppe Calligaris (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Mario Albertucci (M)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Enrico Romagnoli (E)

Department of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Vito Ramazzotti (V)

Cardiovascular Sciences Department, San Giovanni Addolorata Hospital, Rome, Italy.

Corrado Tamburino (C)

Cardio-Thoracic Vascular Department, Azienda ospedaliero-Universitaria "Policlinico Vittorio-Emanuele", University of Catania, Catania, Italy.

Filippo Crea (F)

Department of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Yukio Ozaki (Y)

Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan.

Eloisa Arbustini (E)

Centre for Inherited Cardiovascular Diseases, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.

Francesco Prati (F)

Cardiovascular Sciences Department, San Giovanni Addolorata Hospital, Rome, Italy; Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy; Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain; UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy. Electronic address: fprati@hsangiovanni.roma.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH